We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
- Authors
Jakesz, Raimund; Jonat, Walter; Gnant, Michael; Mittlboeck, Martina; Greil, Richard; Tausch, Christoph; Hilfrich, Joern; Kwasny, Werner; Menzel, Christian; Samonigg, Hellmut; Seifert, Michael; Gademann, Guenther; Kaufmann, Manfred; Wolfgang, Johann; ABCSG and the GABG
- Abstract
Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy. We investigate whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole.
- Publication
Lancet (London, England), 2005, Vol 366, Issue 9484, p455
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(05)67059-6